Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Pycnogenol for the Treatment of Lymphedema of the Arm in Breast Cancer Survivors

This study has been completed.
Information provided by:
National Center for Complementary and Integrative Health (NCCIH) Identifier:
First received: July 14, 2003
Last updated: April 21, 2008
Last verified: April 2008
The goal of this study is to evaluate the effectiveness of a standardized botanical extract of Pycnogenol as a treatment for stable arm lymphedema in breast cancer survivors.

Condition Intervention Phase
Drug: Pycnogenol
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double-Blind
Primary Purpose: Treatment
Official Title: Pycnogenol for the Treatment of Lymphedema of the Arm in Breast Cancer Survivors

Resource links provided by NLM:

Further study details as provided by National Center for Complementary and Integrative Health (NCCIH):

Estimated Enrollment: 26
Study Start Date: August 2003
Study Completion Date: August 2007
Primary Completion Date: August 2007 (Final data collection date for primary outcome measure)
Detailed Description:
Lymphedema of the arm affects the function and self-image of approximately 600,000 of the 2 million breast cancer survivors in the United States. Chronic lymphedema can lead to recurrent infections and permanent swelling, in some cases impairing function. Although various methods of massage and the use of non-elastic compression "sleeves" have been shown to decrease the severity of lymphedema, these methods of physical therapy are limited in terms of patient acceptance, compliance, and by the availability of trained therapists. There is presently no pharmacologic treatment that has proven effective in treating or preventing the development of lymphedema in women treated for breast cancer. This is a double-blind, placebo-controlled trial of an extract of the bark of the French maritime pine tree (Pycnogenol(r)) as a treatment for arm lymphedema in breast cancer survivors. Pycnogenol(r) is widely used in Europe for lymphedema of the leg and varicose veins, and is thought to act by several mechanisms including vascular permeability and vascular constriction. The development of such a therapeutic approach would therefore constitute a major breakthrough in the treatment of this common symptom of breast cancer lymphedema. Bioelectric impedance is a painless, quick, and easily-performed method of estimating the extracellular and total water volume of the body or segment, such as the arm. We will compare the correlation of both a single- and a multiple-frequency bioelectric impedance instrument in measuring change in arm volume to a standard assessment using water displacement. We expect that bioelectric impedance will prove faster and more sensitive to changes in extracellular water (lymphedema) than the water displacement method. We also propose to use a small oral dose of midazolam and single blood sampling to screen for effects of Pycnogenol(r) on the activity of the common drug metabolizing enzyme CYP3A4. For those subjects who are already receiving digoxin, we will use digoxin urine excretion to screen for effects of the botanical upon the activity of P-glycoprotein. Finally, we will continue the evaluation of a new questionnaire of lymphedema symptoms presently being tested as a tool for assessing the severity and improvement of symptoms with treatment. In summary, the successful completion of this research can be expected to provide an alternative therapy and new instruments for treating and measuring lymphedema.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion criteria:

  • Unilateral (ipsilateral to breast cancer resection side) lymphedema of the upper extremity.
  • Extravascular water ration of > 1.07/1 between affected vs. normal arm using multiple frequency bioelectric impedence
  • Patient is > 2months from last surgical or radiation treatment to the affected axilla
  • Renal and hepatic function:

Creatinine clearance > 50ml/min, total bili <2 mg/dl, transaminases <1.5 x ULN

  • Patient not pregnant or breastfeeding. Use of barrier contraception if sexually active.
  • ECOG performance of 0-2
  • Patient not allergic to pycnogenol

Exclusion criteria:

  • Patients treated with their first course of chemotherapy or radiation
  • Chemotherapy or radiation to axillary lymph node will exclude patients for 8 weeks following treatment
  • Patients with more than one episode of arm cellulitis, venous clot, or woody fibrosis of the affected arm. Antibiotics used to treat cellulitis must be completed at least 4 weeks prior to initial screening
  • Patients with a defibrillator Midazolam study only: Patients requiring or benefiting from supplemental oxygen, patients allergic to cherries
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00064857

United States, Wisconsin
University of Wisconsin Comprehensive Cancer Center and School of Pharmacy
Madison, Wisconsin, United States, 53706
Sponsors and Collaborators
National Center for Complementary and Integrative Health (NCCIH)
Study Chair: James F. Cleary, M.B.B.S. University of Wisconsin, Madison
  More Information Identifier: NCT00064857     History of Changes
Other Study ID Numbers: R21AT001724-01 ( US NIH Grant/Contract Award Number )
Study First Received: July 14, 2003
Last Updated: April 21, 2008

Keywords provided by National Center for Complementary and Integrative Health (NCCIH):
plant preparation
herbal preparation
pine bark extract

Additional relevant MeSH terms:
Lymphatic Diseases
Adjuvants, Immunologic
Immunologic Factors
Physiological Effects of Drugs
Platelet Aggregation Inhibitors processed this record on April 28, 2017